Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CEO Sean Duffy sold 21,572 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.62, for a total value of $509,530.64. Following the sale, the chief executive officer owned 411,861 shares in the company, valued at approximately $9,728,156.82. The trade was a 4.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Omada Health Stock Performance
Shares of OMDA stock opened at $22.77 on Friday. The company has a market cap of $1.39 billion, a P/E ratio of 455.40 and a beta of 1.86. The stock has a 50 day simple moving average of $22.70 and a two-hundred day simple moving average of $17.58. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92.
Omada Health (NASDAQ:OMDA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. The firm had revenue of $87.83 million for the quarter, compared to analysts’ expectations of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. On average, research analysts predict that Omada Health, Inc. will post 0.09 earnings per share for the current year.
Hedge Funds Weigh In On Omada Health
Analyst Upgrades and Downgrades
Several research firms have recently commented on OMDA. Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. boosted their price objective on Omada Health from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Wells Fargo & Company raised their target price on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Barclays raised their price objective on Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Omada Health in a research note on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Omada Health has a consensus rating of “Moderate Buy” and an average price target of $26.50.
Check Out Our Latest Research Report on OMDA
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
- Five stocks we like better than Omada Health
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
